SpecialtyVETPATH Taps Proscia For A Full Transformation Of Its Pathology Operations
admin@pathologynews.com2024-04-23T12:00:03+00:00Advancing diagnosis and research with an enterprise software platform
Advancing diagnosis and research with an enterprise software platform
Digital Pathology & AI Congress: USA. Utilizing Digital Pathology & AI to advance pathology practice, enable enhanced patient care and further drug discovery.
All six NHS Trusts within the West Yorkshire Pathology Network are now live on the NPIC digital pathology platform, after Airedale NHS Foundation Trust and Bradford Teaching Hospitals NHS Foundation Trust recently joined the other four NHS Trusts within the West Yorkshire area, (collectively known as the West Yorkshire Association of Acute Trusts [WYAAT]) and have now gone live.
Scaling image analysis capabilities and expanding access to cutting-edge AI through AISight platform integration with Google Cloud
In the fall of 2023, Paige, a leading healthcare technology company specializing in AI for cancer diagnosis, announced a landmark collaboration with Microsoft Research to develop what is being celebrated as the world's largest image-based AI model dedicated to cancer research. The fruition of this collaboration, the Foundation Model named Virchow, has not only been revealed, but has also showcased substantial advancements in its capabilities in less than six months.
Following the success of our International Spatial Biology Congress: Europe for the last 2 years, we are delighted to be hosting a Spatial Biology event in America. In this rapidly developing field, spatial biology provides significant potential for creating novel clinical insights. Recent technological advancements in spatial biology have provided insights into new strategies to prevent and treat disease, particularly the interactions between the tumour and the tumour microenvironment in cancers to target patients to more specific treatments. New spatial research has focused more on the analysis of the transcriptome, epigenome, and metabolomics as well as gene and protein expression to discover how these influence cellular and molecular distributions and interactions.
In the ever-changing landscape of pathology, the accurate assessment of mitotic activity plays a crucial role in diagnosing and managing various diseases, including cancer. Traditionally, pathologists manually count mitotic figures under a microscope in a labor-intensive and time-consuming process that is highly prone to inter-observer variability. However, with the rapid development of Artificial Intelligence (AI), we anticipate [...]
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of Patholytix Foresight, a non-clinical AI decision support tool developed in collaboration with Deciphex, an innovator in pathology AI. By combining Deciphex’s unique digital pathology solutions with Charles River’s robust non-clinical pathology programs, clients of both organizations will have access to the technology-driven capabilities to accelerate primary evaluation and peer review in toxicologic pathology assessment, enhancing decision-making in drug discovery and safety assessment.
Lumea, a forefront innovator in digital pathology, is pleased and honoured to be announced the winner of Utah’s Best in State award for Medical Innovation
Dr. Yunlu Zou whitepaper focuses on the Aperio GT 450 Quality Control Process, featuring the Automated Narrow Stripe, one of the new features for researchers.
© Copyright 2025, Bioincyte Ltd
PathologyNews Chat
